Homology Medicines Inc ASGCT Symposium Transcript
Good day, and welcome to the Homology Medicines ASGCT Symposium. I would now like to turn the call over to Theresa McNeely, Chief Communications Officer and Patient Advocate. You may begin.
Thank you, operator. Good morning, everyone, and thank you for joining us. I know it's a little early, but we have a lot to share with you today. So thank you for coming.
But before we begin, we would like to remind you that we'll be making certain remarks today about Homology's future expectations, plans and prospects, which constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those discussed in the Risk Factors section of our most recent 10-Q that we filed on Monday with the SEC. It can also be accessed on our website.
In addition,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |